Regulation - Merck & Co, Anti-Arthritics/Rheumatics

Filter

Popular Filters

Merck & Co closes odanacatib trial early on good results in osteoporosis

13-07-2012

US drug giant Merck & Co (NYSE: MRK) says it is halting a Phase III trial of its investigational osteoporosis…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalRegulationResearch

Back to top